DEA's Mysterious Memo on Dr. Konen: Details? What Details?
Published Date: 8/20/2025
Notice
Summary
Dr. Andrew Konen from Dallas lost his DEA license because he wrote lots of prescriptions for strong drugs in ways that weren’t legal or safe. He didn’t show up to defend himself, so the government decided to revoke his registration and deny any future applications. This means he can’t legally prescribe controlled substances anymore, starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Konen
The Drug Enforcement Administration revoked Andrew Konen, M.D.'s DEA certificate of registration (BK4924139) and denied all pending registration applications he had in Texas. The OSC that led to this action was issued August 12, 2024, and the Decision and Order was published August 20, 2025.
Default Rule: Missed Deadlines Can Forfeit Hearing
Under DEA rules (21 CFR 1301.37(d) and 1301.43), a person served with an Order to Show Cause has 30 days to request a hearing and answer the allegations; an unexcused default can be deemed a waiver of the right to a hearing and an admission of the OSC's factual allegations. The final rule implementing this framework became effective December 14, 2022, and was applied in this case after missed prehearing deadlines in September–October 2024.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2025-15865 — Agency Information Collection Activity: Application for Disability Compensation and Related Compensation Benefits
The VA wants your thoughts on updating the form veterans use to apply for disability benefits. This is a chance to help make the process smoother and easier for those who served. You’ve got 60 days to share your feedback—no money changes yet, just a heads-up to improve the paperwork!
Next: 2025-15867 — Kenneth Pherson, D.O.; Decision and Order
Kenneth Pherson, D.O., lost his DEA registration because he no longer has permission to handle controlled substances in Florida. He didn’t ask for a hearing after being notified, so the DEA moved forward and officially revoked his registration. This means Dr. Pherson can’t legally prescribe or manage controlled drugs anymore, effective immediately.